Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by alanmar1on Oct 02, 2021 11:01am

278 Views

Post# 33957424

Acasti pharma

This is directed to Francine ,a dedicated ACST follower and righty so based on data available.
Francine, if you still own ACST stock I recomend you move some of your investment into WML.
You should not have to wait too long to gain a very signifcant profit.You can then move some or all back into ACST which could pleased in the next 3 months

<< Previous

Bullboard Posts

Next >>

How to interpret movements in the price of gold